Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?

Future Oncol. 2022 Dec;18(39):4235-4238. doi: 10.2217/fon-2022-0668. Epub 2023 Jan 18.

Authors

Bulent Cetin¹, Chiara A Wabl², Ozge Gumusay³

Affiliations

¹ Department of Internal Medicine, Division of Medical Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun, 55280, Turkey.
² University of California, San Francisco, School of Medicine, San Francisco, CA 94143, USA.
³ Department of Internal Medicine, Division of Medical Oncology, School of Medicine, Acibadem University, Istanbul, 34752, Turkey.

PMID: 36651304
DOI: 10.2217/fon-2022-0668

No abstract available

Keywords: PARP inhibitors; advanced prostate cancer; homologous recombination repair.

MeSH terms

Androstenes / therapeutic use
DNA Repair
Humans
Male
Poly(ADP-ribose) Polymerase Inhibitors* / adverse effects
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / pathology

Substances

Poly(ADP-ribose) Polymerase Inhibitors
abiraterone
Androstenes